197 related articles for article (PubMed ID: 25445556)
1. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.
Wiegel T; Bartkowiak D; Bottke D; Thamm R; Hinke A; Stöckle M; Rübe C; Semjonow A; Wirth M; Störkel S; Golz R; Engenhart-Cabillic R; Hofmann R; Feldmann HJ; Kälble T; Siegmann A; Hinkelbein W; Steiner U; Miller K
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):288-94. PubMed ID: 25445556
[TBL] [Abstract][Full Text] [Related]
2. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
Murgic J; Jaksic B; Prpic M; Kust D; Bahl A; Budanec M; Prgomet Secan A; Franco P; Kruljac I; Spajic B; Babic N; Kruslin B; Zovak M; Zubizarreta E; Rosenblatt E; Fröbe A
Radiat Oncol; 2021 May; 16(1):88. PubMed ID: 33980277
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant radiotherapy after prostatectomy for prostate cancer in Japan: a multi-institutional survey study of the JROSG.
Aoki M; Mizowaki T; Akimoto T; Nakamura K; Ejima Y; Jingu K; Tamai Y; Nakajima N; Takemoto S; Kokubo M; Katoh H
J Radiat Res; 2014 May; 55(3):533-40. PubMed ID: 24385470
[TBL] [Abstract][Full Text] [Related]
4. The natural history of a delayed detectable PSA after radical prostatectomy.
Szymaniak JA; Washington SL; Cowan JE; Cooperberg MR; Lonergan PE; Nguyen HG; Meng MV; Carroll PR
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):759-764. PubMed ID: 36765111
[TBL] [Abstract][Full Text] [Related]
5. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047).
Parker CC; Petersen PM; Cook AD; Clarke NW; Catton C; Cross WR; Kynaston H; Parulekar WR; Persad RA; Saad F; Bower L; Durkan GC; Logue J; Maniatis C; Noor D; Payne H; Anderson J; Bahl AK; Bashir F; Bottomley DM; Brasso K; Capaldi L; Chung C; Cooke PW; Donohue JF; Eddy B; Heath CM; Henderson A; Henry A; Jaganathan R; Jakobsen H; James ND; Joseph J; Lees K; Lester J; Lindberg H; Makar A; Morris SL; Oommen N; Ostler P; Owen L; Patel P; Pope A; Popert R; Raman R; Ramani V; Røder A; Sayers I; Simms M; Srinivasan V; Sundaram S; Tarver KL; Tran A; Wells P; Wilson J; Zarkar AM; Parmar MKB; Sydes MR;
Ann Oncol; 2024 Apr; ():. PubMed ID: 38583574
[TBL] [Abstract][Full Text] [Related]
6. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.
Den RB; Yousefi K; Trabulsi EJ; Abdollah F; Choeurng V; Feng FY; Dicker AP; Lallas CD; Gomella LG; Davicioni E; Karnes RJ
J Clin Oncol; 2015 Mar; 33(8):944-51. PubMed ID: 25667284
[TBL] [Abstract][Full Text] [Related]
7. Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial.
McKay RR; Xie W; Yang X; Acosta A; Rathkopf D; Laudone VP; Bubley GJ; Einstein DJ; Chang P; Wagner AA; Kane CJ; Preston MA; Kilbridge K; Chang SL; Choudhury AD; Pomerantz MM; Trinh QD; Kibel AS; Taplin ME
Cancer; 2024 May; 130(9):1629-1641. PubMed ID: 38161319
[TBL] [Abstract][Full Text] [Related]
8. Impact of radiation doses on clinical relapse of biochemically recurrent prostate cancer after prostatectomy.
Takano S; Tomita N; Niwa M; Torii A; Takaoka T; Kita N; Uchiyama K; Nakanishi-Imai M; Ayakawa S; Iida M; Tsuzuki Y; Otsuka S; Manabe Y; Nomura K; Ogawa Y; Miyakawa A; Miyamoto A; Takemoto S; Yasui T; Hiwatashi A
Sci Rep; 2024 Jan; 14(1):113. PubMed ID: 38167430
[TBL] [Abstract][Full Text] [Related]
9. Cell-cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone.
Swanson GP; Lenz L; Stone S; Cohen T
Prostate; 2021 Mar; 81(4):261-267. PubMed ID: 33475174
[TBL] [Abstract][Full Text] [Related]
10. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA.
Barrou B; Benoît G; Ouldkaci M; Cussenot O; Salcedo M; Agrawal S; Massicard S; Bercovici N; Ericson ML; Thiounn N
Cancer Immunol Immunother; 2004 May; 53(5):453-60. PubMed ID: 14760510
[TBL] [Abstract][Full Text] [Related]
11. Ultrasensitive PSA: rethinking post-surgical management for node positive prostate cancer.
Aguiar JA; Li EV; Ho A; Bennett R; Li Y; Neill C; Schaeffer EM; Patel HD; Ross AE
Front Oncol; 2024; 14():1363009. PubMed ID: 38655143
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for prostate-specific antigen persistence in pT3aN0 prostate cancer after robot-assisted laparoscopic radical prostatectomy: a retrospective study.
Kim JS; Chung JH; Song W; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Lee HM; Jeon SS
J Yeungnam Med Sci; 2023 Oct; 40(4):412-418. PubMed ID: 37376735
[TBL] [Abstract][Full Text] [Related]
13. Decipher Score predicts prostate specific antigen persistence after prostatectomy.
Treacy PJ; Falagario UG; Magniez F; Ratnani P; Wajswol E; Martini A; Jambor I; Wiklund P; Bentellis I; Barthe F; Kyprianou N; Durand M; Steffens D; Karunaratne S; Leslie S; Thanigasalam R; Tewari A
Minerva Urol Nephrol; 2023 Oct; 75(5):583-590. PubMed ID: 37728494
[TBL] [Abstract][Full Text] [Related]
14. Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: Long-Term Results From the PKUFH Randomized Phase 3 Trial.
Li HZ; Qi X; Gao XS; Li XM; Qin SB; Li XY; Ma MW; Bai Y; Chen JY; Ren XY; Li XY; Wang D
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):697-705. PubMed ID: 37717784
[TBL] [Abstract][Full Text] [Related]
15. Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations.
Morgentaler A; Conners WP
Asian J Androl; 2015; 17(2):206-11. PubMed ID: 25652633
[TBL] [Abstract][Full Text] [Related]
16. Chromosome 8q arm overexpression is associated with worse prostate cancer prognosis.
Alshalalfa M; Nguyen TT; Stopsack KH; Khan A; Franco I; Seldon C; Swami N; Jin W; Meiyappan K; Ton M; Venstrom JM; Dee EC; Mahal BA
Urol Oncol; 2023 Feb; 41(2):106.e17-106.e23. PubMed ID: 36400666
[TBL] [Abstract][Full Text] [Related]
17. An integrated radiology-pathology machine learning classifier for outcome prediction following radical prostatectomy: Preliminary findings.
Hiremath A; Corredor G; Li L; Leo P; Magi-Galluzzi C; Elliott R; Purysko A; Shiradkar R; Madabhushi A
Heliyon; 2024 Apr; 10(8):e29602. PubMed ID: 38665576
[TBL] [Abstract][Full Text] [Related]
18. Radical prostatectomy versus radiotherapy as local therapy for primary tumors in patients with oligometastatic prostate cancer.
Ham WS; Park JS; Jang WS; Kim J
Front Oncol; 2024; 14():1368926. PubMed ID: 38544836
[TBL] [Abstract][Full Text] [Related]
19. Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review.
von Eyben FE; Kairemo K; Kapp DS
Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672176
[TBL] [Abstract][Full Text] [Related]
20. Increased Preoperative Plasma Level of Microbial 16S rDNA Translocation Is Associated With Relapse After Prostatectomy in Prostate Cancer Patients.
Ou T; Zhou Z; Turner DP; Zhu B; Lilly M; Jiang W
Front Oncol; 2019; 9():1532. PubMed ID: 32010622
[No Abstract] [Full Text] [Related]
[Next] [New Search]
